Three years clinico-epidemiological study of breast cancer patients at Clinical Oncology Department, Tanta University | ||||
| Egyptian Journal of Cancer and Biomedical Research | ||||
| Volume 8, Issue 4, December 2024, Page 24-32 PDF (735.47 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcbr.2024.318336.1368 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amira Abd Elfattah Farrag  ; Alaa Mohamed Maria; Fatma Gharieb Kheirallah; Rabab Mahmmoud Abosobba
| ||||
| Clinical Oncology Department, Faculty of Medicine, Tanta University, Egypt | ||||
| Abstract | ||||
| Background: Breast cancer represents the most frequently diagnosed cancer affecting women globally and is the second leading cause of cancer death among women, following lung cancer. Similarly, in Egypt, breast cancer is the most prevalent form of cancer in women, constituting 35.1% of all female cancer cases. Aim: This study describes the clinico-epidemiological and pathological pattern of breast cancer, including the analysis of investigational methods and treatment lines. Patients and Methods: This retrospective descriptive Hospital based clinico-epidemiological study was held at Clinical Oncology Department, Tanta University Hospitals for patients (n=1,210) who were histo-pathologically proven to have breast cancer presented at our department throughout the period between January 2019 to 31st December 2021. Results: Breast cancer cases represented about 20% of all cases in each year. The mean age was 53 (range 24 -90) years. Postmenopausal patients represented 63%. 43% of patients presented with stage II. The most common subtype was invasive ductal carcinoma (IDC; 88%). Most cases were luminal B (48.4%). At the end of of the study, 19.7% of non-metastatic patients developed metastasis either solitary or multiple, where bone was the most common site of metastasis followed by lung. 94.5% of all patients were alive. Conclusion: Breast cancer is a heterogenous disease and the treatment differs according to molecular type and stage. Early-stage breast cancer patients showed better survival than patients with late stage, where luminal cases had better survival than triple negative and HER2 positive cases. | ||||
| Keywords | ||||
| Breast cancer; epidemiology; survival analysis | ||||
|
Statistics Article View: 162 PDF Download: 112 |
||||
